Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma

Study design and baseline characteristics of the 'Watchful Waiting' Study

M. S. Stratton, M. E. Reid, G. Schwartzberg, F. E. Minter, B. K. Monroe, David S Alberts, J. R. Marshall, Frederick R Ahmann

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Impediment of the promotion and progression stages of carcinogenesis of the prostate could have a profound impact on treatment choice and prognosis for prostate cancer. Efficacious chemopreventive agents that elicit their activity by slowing the processes of progression could make watchful waiting a viable alternative for a large population of men or could delay the necessity for surgery, radiation or other more invasive treatment modalities associated with frequent side effects. Reports from the Nutritional Prevention of Cancer (NPC) study reported that dietary supplementation with selenium significantly reduced the risk of developing prostate cancer. These data led to initiation of the Watchful Waiting Study, a phase II, multi-center, randomized, double-blind, placebo-controlled clinical intervention study testing the effects of two doses of selenized yeast on progression of prostate cancer. Participants are men with biopsy-proven prostate cancer who have elected to forgo therapy and be closely followed by 'watchful waiting' that includes quarterly prostate-specific antigen (PSA) screening. Subjects are randomized to receive 200 or 800 μg of selenized yeast or matched placebo daily. Endpoints include time to disease progression and PSA velocity. Secondary endpoints include time to initiation of therapy as well as biochemical markers of disease progression including chromagranin A and alkaline phosphatase. Immunohistochemical analyses for indicators of apoptosis, proliferation and differentiation will be performed on baseline and subsequent prostate biopsy specimens. This report summarizes the primary objectives, research methods and the randomized subjects in this important clinical trial.

Original languageEnglish (US)
Pages (from-to)595-600
Number of pages6
JournalAnti-Cancer Drugs
Volume14
Issue number8
DOIs
StatePublished - Sep 2003

Fingerprint

Watchful Waiting
Selenium
Disease Progression
Prostate
Prostatic Neoplasms
Carcinoma
Prostate-Specific Antigen
Yeasts
Placebos
Biopsy
Therapeutics
Dietary Supplements
Alkaline Phosphatase
Carcinogenesis
Biomarkers
Clinical Trials
Radiation
Apoptosis
Research
Population

Keywords

  • Prostate cancer
  • Selenium
  • Watchful Waiting Study

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma : Study design and baseline characteristics of the 'Watchful Waiting' Study. / Stratton, M. S.; Reid, M. E.; Schwartzberg, G.; Minter, F. E.; Monroe, B. K.; Alberts, David S; Marshall, J. R.; Ahmann, Frederick R.

In: Anti-Cancer Drugs, Vol. 14, No. 8, 09.2003, p. 595-600.

Research output: Contribution to journalArticle

@article{e2970ab0483445f188b126bb338d18f6,
title = "Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: Study design and baseline characteristics of the 'Watchful Waiting' Study",
abstract = "Impediment of the promotion and progression stages of carcinogenesis of the prostate could have a profound impact on treatment choice and prognosis for prostate cancer. Efficacious chemopreventive agents that elicit their activity by slowing the processes of progression could make watchful waiting a viable alternative for a large population of men or could delay the necessity for surgery, radiation or other more invasive treatment modalities associated with frequent side effects. Reports from the Nutritional Prevention of Cancer (NPC) study reported that dietary supplementation with selenium significantly reduced the risk of developing prostate cancer. These data led to initiation of the Watchful Waiting Study, a phase II, multi-center, randomized, double-blind, placebo-controlled clinical intervention study testing the effects of two doses of selenized yeast on progression of prostate cancer. Participants are men with biopsy-proven prostate cancer who have elected to forgo therapy and be closely followed by 'watchful waiting' that includes quarterly prostate-specific antigen (PSA) screening. Subjects are randomized to receive 200 or 800 μg of selenized yeast or matched placebo daily. Endpoints include time to disease progression and PSA velocity. Secondary endpoints include time to initiation of therapy as well as biochemical markers of disease progression including chromagranin A and alkaline phosphatase. Immunohistochemical analyses for indicators of apoptosis, proliferation and differentiation will be performed on baseline and subsequent prostate biopsy specimens. This report summarizes the primary objectives, research methods and the randomized subjects in this important clinical trial.",
keywords = "Prostate cancer, Selenium, Watchful Waiting Study",
author = "Stratton, {M. S.} and Reid, {M. E.} and G. Schwartzberg and Minter, {F. E.} and Monroe, {B. K.} and Alberts, {David S} and Marshall, {J. R.} and Ahmann, {Frederick R}",
year = "2003",
month = "9",
doi = "10.1097/00001813-200309000-00004",
language = "English (US)",
volume = "14",
pages = "595--600",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma

T2 - Study design and baseline characteristics of the 'Watchful Waiting' Study

AU - Stratton, M. S.

AU - Reid, M. E.

AU - Schwartzberg, G.

AU - Minter, F. E.

AU - Monroe, B. K.

AU - Alberts, David S

AU - Marshall, J. R.

AU - Ahmann, Frederick R

PY - 2003/9

Y1 - 2003/9

N2 - Impediment of the promotion and progression stages of carcinogenesis of the prostate could have a profound impact on treatment choice and prognosis for prostate cancer. Efficacious chemopreventive agents that elicit their activity by slowing the processes of progression could make watchful waiting a viable alternative for a large population of men or could delay the necessity for surgery, radiation or other more invasive treatment modalities associated with frequent side effects. Reports from the Nutritional Prevention of Cancer (NPC) study reported that dietary supplementation with selenium significantly reduced the risk of developing prostate cancer. These data led to initiation of the Watchful Waiting Study, a phase II, multi-center, randomized, double-blind, placebo-controlled clinical intervention study testing the effects of two doses of selenized yeast on progression of prostate cancer. Participants are men with biopsy-proven prostate cancer who have elected to forgo therapy and be closely followed by 'watchful waiting' that includes quarterly prostate-specific antigen (PSA) screening. Subjects are randomized to receive 200 or 800 μg of selenized yeast or matched placebo daily. Endpoints include time to disease progression and PSA velocity. Secondary endpoints include time to initiation of therapy as well as biochemical markers of disease progression including chromagranin A and alkaline phosphatase. Immunohistochemical analyses for indicators of apoptosis, proliferation and differentiation will be performed on baseline and subsequent prostate biopsy specimens. This report summarizes the primary objectives, research methods and the randomized subjects in this important clinical trial.

AB - Impediment of the promotion and progression stages of carcinogenesis of the prostate could have a profound impact on treatment choice and prognosis for prostate cancer. Efficacious chemopreventive agents that elicit their activity by slowing the processes of progression could make watchful waiting a viable alternative for a large population of men or could delay the necessity for surgery, radiation or other more invasive treatment modalities associated with frequent side effects. Reports from the Nutritional Prevention of Cancer (NPC) study reported that dietary supplementation with selenium significantly reduced the risk of developing prostate cancer. These data led to initiation of the Watchful Waiting Study, a phase II, multi-center, randomized, double-blind, placebo-controlled clinical intervention study testing the effects of two doses of selenized yeast on progression of prostate cancer. Participants are men with biopsy-proven prostate cancer who have elected to forgo therapy and be closely followed by 'watchful waiting' that includes quarterly prostate-specific antigen (PSA) screening. Subjects are randomized to receive 200 or 800 μg of selenized yeast or matched placebo daily. Endpoints include time to disease progression and PSA velocity. Secondary endpoints include time to initiation of therapy as well as biochemical markers of disease progression including chromagranin A and alkaline phosphatase. Immunohistochemical analyses for indicators of apoptosis, proliferation and differentiation will be performed on baseline and subsequent prostate biopsy specimens. This report summarizes the primary objectives, research methods and the randomized subjects in this important clinical trial.

KW - Prostate cancer

KW - Selenium

KW - Watchful Waiting Study

UR - http://www.scopus.com/inward/record.url?scp=0142061650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142061650&partnerID=8YFLogxK

U2 - 10.1097/00001813-200309000-00004

DO - 10.1097/00001813-200309000-00004

M3 - Article

VL - 14

SP - 595

EP - 600

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -